ArticleThe Prostate2019
Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.
Article in The Prostate, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Prostate Cancer-Associated Fibroblasts: A Review on CAF Functions, Heterogeneity, Resistance Mechanisms, and Future in a Chip.International journal of molecular sciences · 2026Review
- Validation of fibroblast activation protein and α-smooth muscle actin as prognostic biomarkers in prostate cancer through AI-assisted image analysis of dual-marker IHC.The journal of pathology. Clinical research · 2026Article
- Article
- Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- Physics-Informed Autoencoder for Prostate Tissue Microstructure Profiling with Hybrid Multidimensional MRI.Radiology. Artificial intelligence · 2025Article
- Deciphering the Tumor Microenvironment in Prostate Cancer: A Focus on the Stromal Component.Cancers · 2024Review
- Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma.Communications biology · 2024Article
- Prostate Cancer's Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism Manipulation.International journal of molecular sciences · 2024Article
- Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Article
- Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment.Cancers · 2022Review
- An optimized MALDI MSI protocol for spatial detection of tryptic peptides in fresh frozen prostate tissue.Proteomics · 2022Article
- Patterns of indolence in prostate cancer (Review).Experimental and therapeutic medicine · 2022Review
- AI Model for Prostate Biopsies Predicts Cancer Survival.Diagnostics (Basel, Switzerland) · 2022Article
- Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer.Cancer research communications · 2022Article
- Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- High tumor cell platelet-derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma.The journal of pathology. Clinical research · 2021Article
- Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.Immunotherapy · 2021Article
- Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm.Frontiers in cell and developmental biology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor stroma associates with prostate cancer (PCa) progression, but its specific cellular composition and association to patient survival outcome have not been characterized.
methodsWe analyzed stromal composition in human PCa using multiplex immunohistochemistry and quantitative, high-resolution image analysis in two retrospective, formalin-fixed paraffin embedded observational clinical cohorts (Cohort I, n = 117; Cohort II, n = 340) using PCa-specific mortality as outcome measurement.
resultsA high proportion of fibroblasts associated with aggressive disease and castration-resistant prostate cancer (CRPC). In a multivariate analysis, increase in fibroblast proportion predicted poor cancer-specific outcome independently in the two clinical cohorts studied.
conclusionsFibroblasts were the most important cell type in determining prognosis in PCa and associated with CRPC. Thus, the stromal composition could be critically important in developing diagnostic and therapeutic approaches to aggressive prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.